Trial Outcomes & Findings for Deprescribing Potentially Inappropriate Medications in the Emergency Department for Persons Living With Dementia (NCT NCT06273917)
NCT ID: NCT06273917
Last Updated: 2026-07-01
Results Overview
This will be determined if the ED pharmacist sends an electronic message through the EHR to the outpatient prescriber with de-prescribing recommendations for patients who are taking CNS PIMs. This will be performed on Day 0 in the Emergency Department.
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
300 participants
Primary outcome timeframe
24 hours
Results posted on
2026-07-01
Participant Flow
Emergency Department patients with dementia at three different EDs within one health system were recruited from June 1, 2024 - 6/30/2025.
Emergency Department pharmacists approached patients with prior diagnosis of dementia or MCI to perform medication reconciliation
Participant milestones
| Measure |
PRIDE Patients
Community-dwelling adults (age 18+) in the ED with prior outpatient visits within the NM system and a history of dementia or mild cognitive impairment recorded in the NM EHR will be eligible for inclusion. Patients had medication reconciliation conducted by the clinical pharmacist. Patients who were previously prescribed CNS PIMs had deprescribing recommendations communicated by the clinical pharmacist to the outpatient prescriber.
|
|---|---|
|
Overall Study
STARTED
|
300
|
|
Overall Study
COMPLETED
|
299
|
|
Overall Study
NOT COMPLETED
|
1
|
Reasons for withdrawal
| Measure |
PRIDE Patients
Community-dwelling adults (age 18+) in the ED with prior outpatient visits within the NM system and a history of dementia or mild cognitive impairment recorded in the NM EHR will be eligible for inclusion. Patients had medication reconciliation conducted by the clinical pharmacist. Patients who were previously prescribed CNS PIMs had deprescribing recommendations communicated by the clinical pharmacist to the outpatient prescriber.
|
|---|---|
|
Overall Study
Protocol Violation
|
1
|
Baseline Characteristics
Deprescribing Potentially Inappropriate Medications in the Emergency Department for Persons Living With Dementia
Baseline characteristics by cohort
| Measure |
PRIDE Patients
n=300 Participants
Community-dwelling adults (age 18+) in the ED with prior outpatient visits within the NM system and a history of dementia or mild cognitive impairment recorded in the NM EHR will be eligible for inclusion. We will include 290 patients across 3 sites to have medication reconciliation conducted by the clinical pharmacist. Patients who were previously prescribed CNS PIMs will have deprescribing recommendations communicated by the clinical pharmacist to the outpatient prescriber.
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=9 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
10 Participants
n=9 Participants
|
|
Age, Categorical
>=65 years
|
290 Participants
n=9 Participants
|
|
Sex: Female, Male
Female
|
176 Participants
n=9 Participants
|
|
Sex: Female, Male
Male
|
124 Participants
n=9 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=9 Participants
|
|
Race (NIH/OMB)
Asian
|
8 Participants
n=9 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=9 Participants
|
|
Race (NIH/OMB)
Black or African American
|
75 Participants
n=9 Participants
|
|
Race (NIH/OMB)
White
|
197 Participants
n=9 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=9 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
20 Participants
n=9 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
22 Participants
n=9 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
273 Participants
n=9 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
5 Participants
n=9 Participants
|
|
Region of Enrollment
United States
|
300 Participants
n=9 Participants
|
|
Site
Northwestern Medicine Lake Forest Hospital
|
37 Participants
n=9 Participants
|
|
Site
Northwestern Memorial Hospital
|
196 Participants
n=9 Participants
|
|
Site
Northwestern Medicine Palos Hospital
|
67 Participants
n=9 Participants
|
PRIMARY outcome
Timeframe: 24 hoursThis will be determined if the ED pharmacist sends an electronic message through the EHR to the outpatient prescriber with de-prescribing recommendations for patients who are taking CNS PIMs. This will be performed on Day 0 in the Emergency Department.
Outcome measures
| Measure |
Patients With CNS PIMs
n=79 Participants
Patients who had at least one Central Nervous System active Potentially Inappropriate Medication identified on medication reconcilliation
|
PRIDE Patients
n=300 Participants
Community-dwelling adults (age 18+) in the ED with prior outpatient visits within the NM system and a history of dementia or mild cognitive impairment recorded in the NM EHR will be eligible for inclusion. We will include 290 patients across 3 sites to have medication reconciliation conducted by the clinical pharmacist. Patients who were previously prescribed CNS PIMs will have deprescribing recommendations communicated by the clinical pharmacist to the outpatient prescriber.
|
|---|---|---|
|
Participants With Pharmacist Communication of Deprescribing Recommendation
|
78 Participants
|
299 Participants
|
SECONDARY outcome
Timeframe: 24 hoursThis will be determined if the ED pharmacist enters a medication reconciliation document into the EHR. This will occur on Day 0 in the ED.
Outcome measures
| Measure |
Patients With CNS PIMs
n=300 Participants
Patients who had at least one Central Nervous System active Potentially Inappropriate Medication identified on medication reconcilliation
|
PRIDE Patients
Community-dwelling adults (age 18+) in the ED with prior outpatient visits within the NM system and a history of dementia or mild cognitive impairment recorded in the NM EHR will be eligible for inclusion. We will include 290 patients across 3 sites to have medication reconciliation conducted by the clinical pharmacist. Patients who were previously prescribed CNS PIMs will have deprescribing recommendations communicated by the clinical pharmacist to the outpatient prescriber.
|
|---|---|---|
|
Participants With Medication Reconciliation Completed
|
300 Participants
|
—
|
SECONDARY outcome
Timeframe: 90 daysthis will be determined through outpatient pharmacy records at day 90. Deprescribing defined as reduction in dose, quantity, or elimination of the prescription
Outcome measures
| Measure |
Patients With CNS PIMs
n=79 Participants
Patients who had at least one Central Nervous System active Potentially Inappropriate Medication identified on medication reconcilliation
|
PRIDE Patients
n=300 Participants
Community-dwelling adults (age 18+) in the ED with prior outpatient visits within the NM system and a history of dementia or mild cognitive impairment recorded in the NM EHR will be eligible for inclusion. We will include 290 patients across 3 sites to have medication reconciliation conducted by the clinical pharmacist. Patients who were previously prescribed CNS PIMs will have deprescribing recommendations communicated by the clinical pharmacist to the outpatient prescriber.
|
|---|---|---|
|
Participants With Deprescribed Medications
|
26 Participants
|
26 Participants
|
SECONDARY outcome
Timeframe: 90 daysRepeat emergency department visits or hospitalizations within 90 days of deprescribing intervention
Outcome measures
| Measure |
Patients With CNS PIMs
n=78 Participants
Patients who had at least one Central Nervous System active Potentially Inappropriate Medication identified on medication reconcilliation
|
PRIDE Patients
Community-dwelling adults (age 18+) in the ED with prior outpatient visits within the NM system and a history of dementia or mild cognitive impairment recorded in the NM EHR will be eligible for inclusion. We will include 290 patients across 3 sites to have medication reconciliation conducted by the clinical pharmacist. Patients who were previously prescribed CNS PIMs will have deprescribing recommendations communicated by the clinical pharmacist to the outpatient prescriber.
|
|---|---|---|
|
Participants With Repeat ED Visits or Hospitalization
|
44 Participants
|
—
|
Adverse Events
ED Deprescribing Recommendation
Serious events: 0 serious events
Other events: 0 other events
Deaths: 2 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place